Merck & Co., Inc. (MRK)

Merck & Co., Inc. is one of the world’s largest pharmaceutical companies, with a history stretching back more than a century. The company discovers, develops, manufactures, and sells prescription medicines for human and animal health, operating across oncology, immunology, infectious disease, cardiovascular and metabolic health, and vaccines. It is an American multinational firm headquartered in Rahway, New Jersey, though it operates research, manufacturing, and sales operations across dozens of countries. Merck’s shares trade on the NASDAQ under the ticker MRK.

From a pharmacist’s apprenticeship to a global medicines house

Merck’s origins lie not in the United States but in Germany. The company traces its roots to 1668 in Darmstadt, when a pharmacist named Friedrich Jacob Merck began his trade. For more than two centuries it remained a German pharmaceutical enterprise, but the twentieth century splintered the family into separate geographic territories. When World War II ended, the U.S. operations (which had operated under the name Merck & Co. since 1903) became independent of the German parent. The company that emerged from that break became a powerhouse of American medicine.

Through the 1950s and 1960s, Merck became synonymous with breakthrough antibiotics and vaccines. The company brought penicillin to mass production, developed streptomycin for tuberculosis, and pioneered measles and mumps vaccines. These were not merely commercial successes; they reshaped public health. By the 1970s and 1980s, Merck had evolved into a company that invested heavily in research and development, building one of the largest drug-discovery operations in the world. The company’s leadership in that era, particularly under CEO Roy Vagelos, made a deliberate bet that superior research would drive long-term returns.

That bet paid off through a series of blockbuster drugs: Vasotec (for hypertension), Mevacor (a cholesterol-lowering statin), and later Vioxx (an anti-inflammatory). Vasotec and Mevacor especially became household names among cardiologists and became the anchors of Merck’s business through the 1990s and into the 2000s. The company’s portfolio depth meant that when one drug’s patent expired, others were mature enough to sustain profits.

The Vioxx crisis in 2004 marked a turning point. The pain medication, which Merck had marketed to millions of patients, was found to increase the risk of heart attacks and strokes at higher doses and longer durations. Merck withdrew it from the market and eventually settled lawsuits for billions of dollars. The episode was humbling and forced the company to rethink both its safety protocols and the risks of concentrating its franchise on a single blockbuster. It also accelerated a broader shift in the industry toward vaccines and immunology, areas where Merck had established footholds but had not prioritized.

The modern Merck: vaccines, oncology, and immunology

Since the Vioxx withdrawal, Merck has deliberately repositioned itself around vaccines, immunology, and oncology — therapeutic areas where the science can support high prices and where unmet medical needs remain vast. The company’s work in human papillomavirus (HPV) prevention exemplifies this shift. Merck’s Gardasil, approved in 2006, became one of the most important vaccines of the modern era, preventing several types of cancer caused by HPV. The vaccine generated billions in annual sales and changed the epidemiology of cervical cancer in countries where it was widely administered.

Oncology became a second pillar. Merck invested substantially in cancer immunotherapy, the approach of harnessing the body’s own immune system to fight tumors. The company’s Keytruda, approved by the FDA in 2014, became one of the most commercially successful cancer drugs ever made. Keytruda represented a new class of medicine called checkpoint inhibitors — drugs that free up the immune system to attack cancer cells. By the early 2020s, Keytruda alone accounted for more than ten percent of Merck’s annual revenue and had been approved for dozens of tumor types and stages. The drug’s success drove Merck to expand its oncology portfolio through both internal research and acquisition.

Acquisitions have become central to Merck’s strategy for filling its pipeline. In 2017, the company acquired Oncobiologics, strengthening its portfolio of cancer therapies. The acquisition of Acceleron Pharma in 2021 added a promising rare-disease franchise. These deals reflect a pragmatic reality: not every promising drug can be discovered internally, and buying proven or near-proven candidates reduces the risk of having a barren pipeline.

Merck also owns a significant animal-health business, operating under the name MSD Animal Health in most markets. This segment serves veterinarians and farmers with vaccines and medicines for livestock, pets, and poultry. The veterinary pharmaceutical market is smaller than human pharmaceuticals but grows steadily and offers recurring revenue from farmers who must vaccinate their animals regularly.

How Merck makes money

Prescription drugs — human and animal — are Merck’s core business. Revenue comes from the sale of branded medicines, and the margins are substantial because of the intellectual property protection patent law affords. When a drug is under patent, competitors cannot legally manufacture an identical product, giving Merck years or decades of exclusive sales at whatever price the market will bear. Governments set some limits through regulation and negotiation, but the window of exclusivity is enormously valuable.

Merck operates in a geography-dependent way: the United States, Europe, Japan, and a growing set of emerging markets. The U.S. market pays the highest prices and absorbs a large fraction of Merck’s revenue, but regulatory pressure to negotiate prices has increased in recent years. In Europe, governments or government-connected bodies negotiate prices directly, paying lower rates than the U.S. In emerging markets, the volumes are often large but unit prices are much lower.

The life cycle of a Merck drug typically spans three phases: exclusivity (patent protection), where pricing is high and competition is limited; loss of exclusivity (patent expiration), when generic manufacturers can legally copy the drug and unit sales often collapse; and sometimes, a small residual business from patients who prefer the branded version or physicians who prescribe by brand. The tail is usually brief. Merck’s continued success depends on having enough drugs in the first phase to offset revenue losses in the second and third.

The patent cliff and the pipeline problem

Like every pharmaceutical company, Merck faces a recurring challenge: drugs lose patent protection. When that happens, generic versions enter the market within months, and the branded manufacturer’s sales typically fall by eighty or ninety percent. A company whose pipeline does not replenish its portfolio of patent-protected drugs will see revenue contract sharply. Merck has been exposed to this dynamic before. Vasotec, Mevacor, and several other 1990s blockbusters eventually lost exclusivity.

The company’s response is to invest between five and ten percent of annual revenue into research and development each year. That spending goes into early-stage discovery, clinical trials, manufacturing process development, and regulatory affairs. The goal is to keep a portfolio of drugs at various stages of development, with new approvals hitting the market roughly as older drugs lose patent protection. This is expensive, time-consuming, and uncertain — for every drug that is approved, ten or fifteen others fail in clinical trials or show insufficient efficacy.

Merck’s success in oncology with Keytruda bought the company time, but investors and analysts watch the pipeline closely. The question is whether Merck has enough clinical-stage programs to sustain revenues when Keytruda eventually faces competition from other checkpoint inhibitors (which it increasingly does). The company’s 2021 acquisition of Acceleron was in part an answer to that question.

Competition, regulation, and risk

Merck competes against many other large pharmaceutical companies — Pfizer, Johnson & Johnson, AbbVie, Amgen, and numerous smaller, focused rivals. Competition is both scientific (better drugs win) and commercial (better pricing, better marketing to physicians, better patient support programs). The advantage of a first-to-market breakthrough drug can be substantial, especially for Keytruda competitors that arrived later and must prove superiority in head-to-head trials, but nothing prevents rivals from developing better versions.

The regulatory environment is another constraint. Approval of a new drug by the FDA takes many years and costs hundreds of millions of dollars, and nothing is certain until the data comes in. Once approved, the FDA can withdraw approval if safety problems emerge. Pricing is regulated in most developed countries outside the United States. In the U.S., there is political and legislative pressure to reduce drug prices, particularly for drugs that treat common conditions. Generic manufacturers are a predictable competitive force, but no more so than in past decades.

The largest tail risk is discovery: what if the science underlying Merck’s big bets — such as immunotherapy in cancer — proves more limited than expected? What if Keytruda turns out to work well in only a handful of tumor types despite current approved indications? What if a competitor leapfrogs Merck with a fundamentally better approach? These are real possibilities, which is why Merck maintains a broad portfolio rather than betting everything on one approach.

How to research Merck as an investment

Merck’s annual 10-K filing (SEC CIK 0000310158) is the authoritative source for detailed revenue breakdowns by drug and geography, and it lays out the key risks the company faces. The investor presentation that accompanies quarterly earnings calls provides commentary on clinical trials, regulatory progress, and management’s thinking about the pipeline. Watching for Phase III trial results — the final stage before FDA submission — is a useful way to track whether Merck’s pipeline is generating credible candidates.

A few metrics illuminate the business. The ratio of research and development spending to annual revenue shows the pace at which Merck is investing in future drugs. The number of drugs in clinical development by stage (Phase I, II, or III) gives a rough picture of how full the pipeline is. Keytruda’s revenue trend, as a percentage of total revenue, shows how dependent Merck is on a single product — a measure of concentration risk. The gross margin on prescriptions drugs, compared to other large pharmaceutical companies, reflects competitive positioning and pricing power. As with any individual security, Merck’s shares trade on public exchanges, and nothing here is a recommendation — only a guide to the business and its key drivers.